DYSPORT 500U
DYSPORT is a highly purified injectable formulation of Botulinum Toxin Type A, a neurotoxin derived from Clostridium botulinum. Each vial contains 500 units (U) of active toxin and is approved for both aesthetic and therapeutic use.
Indication
Moderate to Severe Glabellar Lines
Dysport effectively targets frown lines between the eyebrows by temporarily reducing muscle activity. When administered into the corrugator and procerus muscles, it smooths existing wrinkles and prevents new ones from forming, restoring a relaxed and rejuvenated appearance.
Mechanism of Action
Following intramuscular injection, Dysport inhibits the release of acetylcholine at the neuromuscular junction, resulting in localized and reversible muscle relaxation. Its precise action ensures that only the treated areas are affected, minimizing impact on surrounding muscles.
Clinical Profile
Onset of Action: 2–5 days post-injection
Peak Effect: Approximately 2 weeks
Duration: 3–4 months (varies by area and individual response)
Dosage & Reconstitution
Reconstitute with preservative-free 0.9% sodium chloride:
-
1.0 mL saline → 50 U per 0.1 mL
-
2.5 mL saline → 20 U per 0.1 mL
-
5.0 mL saline → 10 U per 0.1 mL
Use the reconstituted solution within 24 hours. Administer according to approved clinical dosing guidelines for each indication.
Aesthetic Applications
-
Glabellar lines
-
Forehead lines
-
Crow’s feet
Therapeutic Applications
-
Cervical dystonia
-
Upper and lower limb spasticity
-
Chronic migraine prophylaxis
-
Axillary hyperhidrosis
-
Blepharospasm
Chemical & Physical Properties
Formula: C₆₇₆₀H₁₀₄₄₇N₁₇₄₃O₂₀₁₀S₃₂
Molar Mass: ≈ 149,320 g/mol
Log P: –0.368 (low lipid solubility)
Stability: Stable at 14.86 °C / 0.1011 MPa for therapeutic use
Storage
Store lyophilized vials at 2–8°C. Do not freeze.
After reconstitution, maintain between 2–8°C and use within 24 hours.
Safety & Precautions
Common side effects include injection-site pain, swelling, bruising, headache, and temporary eyelid or eyebrow ptosis.
Rare but serious reactions may include dysphagia, respiratory difficulty, or speech impairment, particularly at higher doses.
Dysport should be administered only by qualified healthcare professionals in appropriate medical settings.
